Navigation Links
Wyeth Receives Approvable Letter From FDA for Bazedoxifene for the Treatment of Postmenopausal Osteoporosis
Date:5/23/2008

he disease will increase from almost 30 million in 2002 to nearly 41 million in 2020. Up to 20 percent of a woman's expected lifetime bone loss can occur in the years immediately following menopause. The treatment of postmenopausal osteoporosis could lead to significant improvement in the overall health for millions of women worldwide as well as reduce costs associated with postmenopausal osteoporosis-related fractures.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and pipeline products (including that there can be no assurance that our pending new drug applications for bazedoxifene will be approved or that the product will ever be successfully commercialized); government cost-containment initiatives; restrictions on third-party payments for our products; substantial competition in our industry, includ
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
2. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
3. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
4. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
7. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
8. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
9. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
10. Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension
11. Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Medical Science Liaisons serve as ... in the healthcare sector. As the impact of technology ... changing how Medical Science Liaisons (MSLs) interact with physicians ... using the tablet to not only share important disease ... coordinate thought leader interactions across geographies and therapeutic areas. ...
(Date:8/22/2014)... 22, 2014 ... has announced the addition of the  "Global ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... instrument for any modern science laboratory as ... materials. It can be broadly classified into ...
(Date:8/22/2014)... DUBLIN , August 22, 2014 /PRNewswire/ ... ) has announced the addition of the  ... to their offering.       (Logo: ... room with a sterile environment in a ... It is equipped with technically advanced equipment, ...
Breaking Medicine Technology:iPads Enhancing Medical Science Liaison Interactions with Thought Leaders, New Study Shows 2Global Laboratory Electronic Balance Market 2014-2018: Key Vendors are A&D Company, Mettler-Toledo, Sartorius and Thermo Fisher 2Global Operating Room Equipment Market 2014-2018: Key Vendors are Getinge, STERIS, Stykron and TRUMPF Medical Systems 2
... Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) ... Letter (CRL) from the U.S. Food and Drug Administration ... for AZ-004 (Staccato® loxapine), submitted as Adusuve™ Staccato® (loxapine) ... is issued by FDA,s Center for Drug Evaluation and ...
... Ltd. (NYSE Amex: CPD ) announced today that ... Executive Officer following the resignation of Jitendra N. Doshi as ... 1, 2010, due to personal and health-related reasons. ... many contributions during his years of service to the Company, ...
Cached Medicine Technology:Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 2Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 3Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 4Alexza Pharmaceuticals Receives Complete Response Letter for AZ-004 (Staccato® Loxapine) NDA 5Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 2Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 3Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status 4
(Date:8/23/2014)... York (PRWEB) August 23, 2014 Dermatophytic ... is one of the most common fungal infections of ... appearance of the nails such as, increased opaqueness and ... specifically describes the dermatophytic invasion of the nail plates ... artificial nail is applied as the nails are abraded ...
(Date:8/23/2014)... Texas (PRWEB) August 23, 2014 ... of the function of the myocardium (the heart ... failure; common symptoms are dyspnea (breathlessness) and peripheral ... are often at risk of dangerous forms of ... most common form of cardiomyopathy is dilated cardiomyopathy. ...
(Date:8/23/2014)... Pittsburgh, PA (PRWEB) August 23, 2014 ... mess when they gave a urine sample," said an ... the entire process easier and mess-free, I came up ... Device to allow urine samples to be collected from ... added peace of mind to patients and staff. The ...
(Date:8/23/2014)... 2014 "Many men refuse to touch ... up getting covered in urine and spit," said an ... bathroom situations, I came up with this hygienic device." ... a man raises the toilet seat before urinating. The ... This reduces contact with dirt and germs. The accessory ...
(Date:8/23/2014)... The report “Polycarbonate Resin Market by Applications & ... and segments the global polycarbonate resin market with ... consumption. It also identifies driving and restraining factors ... of trends, opportunities, burning issues, winning imperatives. The ... forecasted on the basis of major regions such ...
Breaking Medicine News(10 mins):Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Dermatophytic Onychomycosis Therapeutics Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4
... certain but solutions less so, experts say, , , FRIDAY, April 24 ... hard to avoid. But for people in stressful jobs, it,s especially ... protect the heart. , That,s because stress not only has ... but also a second. , "Work stress is bad for ...
... Hope Considered ,Too Important Not To Be Heard,SAN MATEO, ... that "Light of Hope: Help for Children with Autism," ... debut internationally on Friday, April 24, Saturday, April 25 ... during the final week of World Autism Awareness ...
... 2009 Annual Meeting of ShareholdersMCKINNEY, Texas, April 24 TORCHMARK CORPORATION (NYSE: ... 2009 Annual Meeting of Shareholders, When: ... Where: http://www.videonewswire.com/event.asp?id=56940 , How: ... at the, ...
... 24 Pharmatech Oncology, Inc., a Research Management ... launch of their Data Management business unit to ... Oncology Data Management business unit is branded as ... Data Management business unit maintains and processes data ...
... Copenhagen, Denmark, Friday 24 April: HIV positive and ... transplant, according to new research presented today at EASL ... the Study of Liver in Copenhagen, Denmark. , The ... 1 and 5 years between HIV negative and HIV ...
... HealthYes!™ is bringing its life-saving mobile screening services to ... most medically-advanced, state-of-the-art equipment and techniques to screen its ... abdominal aortic aneurysm, osteoporosis, and peripheral artery disease. ... ...
Cached Medicine News:Health News:Work Strife Stresses the Heart 2Health News:Work Strife Stresses the Heart 3Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 2Health News:'Light of Hope: Help for Children with Autism' Ground-Breaking Internet Television Event on April 24 to April 26 Co-Sponsored by Internet Software Leaders 3Health News:Pharmatech Oncology Launches New Data Management Business Unit 2Health News:HIV positive and HIV negative patients have similar survival rates following liver transplant 2Health News:Texas-Based Mobile Health Screening Company Expands into Dallas-Fort Worth 2Health News:Texas-Based Mobile Health Screening Company Expands into Dallas-Fort Worth 3
Right angled 5 mm blunt hook. Overall length: 9.9 inches....
Fine short working end. Overall length: 4.9 inches. Most popular size or model....
11.5 mm curved hook. Flat serrated handle with polished finish. Overall length: 5.9 inches....
Designed for manipulating one piece lenses. The "Y: hook is excellent for capturing haptics and centering the lens. Straight shaft with "Y" shaped tip. Round knurled handle with dull finish. Overall ...
Medicine Products: